Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study
Authors:
Open Access
- 1 June 2025
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 4991-5005
Abstract
Objective: This study aims to evaluate the efficacy and safety of anlotinib combined with immune checkpoint inhibitors (ICIs) in patients with previously immunotherapy-treated extensive-stage small cell lung cancer (ES-SCLC). Methods: This retrospective study screened ES-SCLC patients who experienced failure after prior ICIs-based treatment and received anlotinib combined with ICIs therapy clinically. Anlotinib was administered at a standard dosage, ICIs regimens included PD-1 inhibitors (Tislelizumab, 200 mg; serplulimab, 4.5 mg/kg) and PD-L1 inhibitors. Efficacy and safety data during treatment were retrospectively collected, and patients were followed up regularly to obtain long-term survival data. Subgroup analysis was conducted to identify the differences in treatment outcomes in various baseline characteristics. Results: Of the 68 ES-SCLC patients included, no complete response, 22 patients achieved partial response, 28 had stable disease, 14 experienced disease progression and 4 patients were not available for efficacy. Objective response rate (ORR) was 32.4% (95% CI: 21.5– 44.8%), and disease control rate (DCR) was 73.5% (95% CI: 61.4– 83.5%). The median progression-free survival (PFS) was 5.6 months (95% CI: 3.87– 7.33), the median duration of response (DoR) was 6.8 months (95% CI: 0.80– 12.83). At the data cutoff date, the median follow-up duration was 12.5 months (range: 1.1– 31.5 months), yielding a median overall survival (OS) of 13.2 months (95% CI: 7.09– 19.31). Subgroup analysis highlighted that patients who were previously intolerant to immunotherapy had a longer OS (median OS: 15.5 vs 10.9 months, P = 0.031). Safety analysis showed that 61 patients (89.7%) experienced treatment-related adverse events (TRAEs) of varying severity with 37 patients (54.4%) developing grade 3 or higher. The most common TRAEs included fatigue, nausea and vomiting, hypertension, hematologic toxicity, and liver function abnormalities. Conclusion: Anlotinib combined with ICIs demonstrated that immunotherapy rechallenge in previously ICIs-treated ES-SCLC was feasible and of clinical significance preliminarily. However, larger-scale clinical studies were required to validate these findings subsequently.Keywords
This publication has 44 references indexed in Scilit:
- The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and PD‐1/L1 Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort StudyCancer Medicine, 2024
- Clinical efficacy and safety of immune checkpoint inhibitors plus anlotinib as secondline or subsequent therapy in extensive stage small cell lung cancer: a retrospective studyClinical and Translational Oncology, 2024
- Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancersClinical and Translational Oncology, 2024
- Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockadeCancer Cell, 2024
- Emerging Strategies for the Treatment of Small Cell Lung CancerJAMA Oncology, 2023
- Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancerCancer Medicine, 2022
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung CancerJAMA, 2022
- Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort studyJournal of Cancer Research and Clinical Oncology, 2022
- Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective studyJournal of Cancer Research and Clinical Oncology, 2021
- Atezolizumab: A Review in Extensive-Stage SCLCDrugs, 2020